Drug Groups

approved

Description

Pamidronic acid (INN) or pamidronate disodium (USAN), marketed as pamidronate disodium pentahydrate under the brand name Aredia, is a bisphosphonate. [Wikipedia]

Indication

For the treatment of moderate or severe hypercalcemia associated with malignancy

Pharmacology

Pamidronate is in a class of drugs called bisphosphonates. Pamidronate reduces breakdown of the bones. Pamidronate is used in the treatment of Paget's disease of bone; to reduce high levels of calcium in the blood associated with malignancy (cancer); and to reduce the breakdown of bone due to metastases of breast cancer or multiple myeloma.

Toxicity

Side effects include an allergic reaction, kidney problems, seizures, low levels of calcium, magnesium, or phosphorus in the blood

Affected Organisms

Biotransformation

Pamidronate is not metabolized and is exclusively eliminated by renal excretion

Absorption

Plasma concentration rises rapidly upon IV administration.

Half Life

The mean ± SD elimination half-life is 28 ± 7 hours

Protein Binding

Approximately 54% to human serum proteins.

Elimination

Pamidronate is not metabolized and is exclusively eliminated by renal excretion.

Clearance

* 107 +/- 50 mlL/min

References

External Links